Piper Jaffray Cos. Analysts Give Alnylam Pharmaceuticals Inc. (ALNY) a $106.00 Price Target
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has been given a $106.00 price target by research analysts at Piper Jaffray Cos. in a report released on Thursday. The firm currently has a a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price target would suggest a potential upside of 192.74% from the stock’s previous close.
Other analysts have also issued reports about the company. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Leerink Swann reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Cowen and Company reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Needham & Company LLC reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, June 13th. Finally, FBR & Co reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, June 10th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $86.00.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 7.84% during mid-day trading on Thursday, hitting $33.37. The company had a trading volume of 4,245,952 shares. The stock’s market cap is $2.86 billion. Alnylam Pharmaceuticals has a 52-week low of $33.28 and a 52-week high of $110.75. The stock’s 50-day moving average is $71.80 and its 200-day moving average is $66.24.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/07/piper-jaffray-cos-analysts-give-alnylam-pharmaceuticals-inc-alny-a-106-00-price-target.html
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The company had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. During the same period last year, the company posted ($0.85) earnings per share. The firm’s revenue was up .2% compared to the same quarter last year. Equities analysts forecast that Alnylam Pharmaceuticals will post ($4.68) earnings per share for the current year.
In other news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the transaction, the chief executive officer now directly owns 148,465 shares in the company, valued at $9,604,200.85. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.00% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $128,000. Seven Eight Capital LLC increased its position in shares of Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 1,800 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $175,000. Bank of Montreal Can acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $193,000. Finally, BlueMountain Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 1,500 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.